Reconnecting to live data…
JournalArta

Target and Genmab Show Strength as S&P 500 Falls

• Target and Genmab led five stocks showing relative strength as the S&P 500 posted its worst weekly point loss on record. • Target raised its full-year EPS outlook on strong comparable sales; Genmab gained on positive cancer trial data. • Cheesecake Factory, Netskope and Welltower also showed strength amid broad market declines. Target and Genmab were among five stocks showing relative strength against the S&P 500 after the index's worst weekly point loss on record, alongside Cheesecake Factory, Netskope and Welltower. Target shares rose 2.7% to 165.83 after the retailer posted 49% EPS growth and 7% revenue growth, raising its full-year EPS forecast to $10.65-$11.40. Truist noted nearly 60% of Target's 5.6% comparable-sales growth came from its Fun 101 category, including trading cards, but cautioned that collectibles demand is fickle and CEO Michael Fiddelke's turnaround needs to broaden into apparel and home goods. Genmab shares fell 1.5% to 50.60 after an October surge driven by positive cancer trial results, including Epkinly beating standard lymphoma treatment, Rina-S succeeding in a late-stage ovarian cancer trial, and petosemtamab cutting death risk by 50% in head-and-neck cancer patients. The stock hit a record 59.97 on October 28. Cheesecake Factory ended the week down 1.1% at 107.95 despite a 7.2% weekly jump, with comparable sales up 15.2% on higher traffic, ticket size and menu/loyalty changes. Netskope drew two analyst price-target hikes (Rosenblatt to 28, TD Cowen to 25) amid AI security concerns, ahead of its December 2 earnings. Welltower posted 25% growth in normalized funds from operations on 38% revenue growth, having closed $13.3 billion of a planned $21 billion in 2024 investments.
November 22, 2026 at 6:41 AMFVRTGTWELL
Read original ↗